Stay Curious. Stay Connected.
MailNewsletters♡Donate Now
Sign up
*Password must be at least 8 characters and contain one uppercase letter, one lowercase letter, one number and one symbol.
Already have an account?
By submitting, you consent that you are at least 18 years of age and to receive information about MPR's or APMG entities' programs and offerings. The personally identifying information you provide will not be sold, shared, or used for purposes other than to communicate with you about MPR, APMG entities, and its sponsors. You may opt-out at any time clicking the unsubscribe link at the bottom of any email communication. View our Privacy Policy.
Sign in to your profile
Forgot Password?
New to MPR News?
Welcome back
to news
for you
Reset Password

Enter the username on file and we'll send you a code to reset your password.

Still require assistance or not sure what your User Name is?
Welcome back
to news
for you
Email Verification

A verification code has been emailed to

Still awaiting the code?
Big Books & Bold Ideas with Kerri Miller
Kerri Miller and Marcheta Fornoff

How quickly will we have a COVID-19 vaccine, and how will we know it's safe?

A subject receives a shot
A subject receives a shot in the first-stage safety study clinical trial of a potential vaccine by Moderna for COVID-19 at the Kaiser Permanente Washington Health Research Institute in Seattle on March 16, 2020. According to results released on Tuesday, July 14, 2020, early-stage testing showed the first COVID-19 vaccine tested in the U.S. revved up people's immune systems the way scientists had hoped. The vaccine is made by the National Institutes of Health and Moderna Inc.
Ted S. Warren | AP Photo file

Go Deeper.

Create an account or log in to save stories.

Log inCreate a free Account

Like this?

Thanks for liking this story! We have added it to a list of your favorite stories.

Show me!

Americans have been getting a lot of confusing messages lately — including from President Trump — about when a COVID-19 vaccine will be ready.

Trump has said a vaccine could be ready this month, but Pfizer officials have said only that they’ll know more about the timing of a vaccine by the end of October. Pfizer and German company BioNTech are working on one of the leading candidates for a U.S. vaccine. The other is being developed by Moderna, which has said its vaccine won’t be widely available until March. 

While the companies are making progress on the vaccines, figuring out how to deploy them once they’re ready could be complicated. And will enough people voluntarily get vaccinated to stop the spread of COVID-19?

On Monday at 9 a.m., MPR News host Kerri Miller spoke with a vaccine researcher and an epidemiologist about the latest efforts to develop a COVID-19 vaccine. 

Guests:

Kumi Smith is an assistant professor in the Division of Epidemiology and Community Health at the University of Minnesota.

Dr. Greg Poland is the director of the Vaccine Research Group at Mayo Clinic.


To listen to the full conversation you can use the audio player above.

Subscribe to the MPR News with Kerri Miller podcast on: Apple Podcasts, Google Podcasts , Spotify or RSS